Top

Published in:

01-10-2004 | Original Research Article

Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?

Authors: Akira Babazono, Motonobu Miyazaki, Hiroshi Une, Eiji Yamamoto, Toshihide Tsuda, Yoshio Mino, Alan L. Hillman

Published in: PharmacoEconomics | Issue 15/2004

Abstract

Background: Helicobacter pylori is regarded as an important cause of both peptic ulcer and chronic gastritis. In particular, seropositivity is highest in patients with duodenal ulcer. No studies have determined whether there are differences in the direct medical costs associated with gastric/duodenal ulcer or inflammation, between seropositive and seronegative patients.

Objective: To examine the relationship between seropositivity for H. pylori and outpatient visits and direct medical costs for gastric/duodenal ulcer or inflammation in Japan from the perspective of the payor and patients.

Methods: Participants were males (n = 653) who worked for an agricultural co-operative in Fukuoka Prefecture, attended an annual health examination (including a written lifestyle and medical survey), belonged to the same health insurance society consistently for 4 years from April 1996 to March 2000, and provided a blood sample. The survey asked about lifestyle, including smoking and drinking, and past medical history. We retrospectively analysed the annual number of outpatient visits per person and outpatient medical cost (Yen [¥], 2000 values) per person for visits relating to gastric or duodenal ulcer or inflammation using International Classification of Diseases (9th edition) — Clinical Modification codes. We assessed for potential confounding factors using analysis of covariance and the chi-square test.

Results: The annual outpatient incidence of disease, the number of visits to physicians, and the medical costs for gastric or duodenal ulcer or inflammation were about 2-fold greater in individuals with antibodies to H. pylori compared with those without antibodies.

Conclusion: Population-based studies and/or randomised controlled clinical trials that target high-risk groups and account for the unique way in which data are collected in Japan are needed to determine whether medical costs for gastric and duodenal ulcer might be reduced by treating asymptomatic patients who have antibodies to H. pylori.

Warren JR, Marshall BJ. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet 1983; I: 1273–5

Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; I: 1311–4CrossRef

Forman D. Helicobacter pylori infection and cancer. Br Med Bull 1998; 54: 71–8PubMedCrossRef

Graham DY, Yamaoka Y. H. pylori and CagA: relationship with gastric cancer, duodenal cancer, and reflex esophagitis and its complications. Helicobacter 1998; 3: 145–51PubMedCrossRef

Marshall BJ, Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication Campylobacter pylori. Lancet 1988; II: 1437–41CrossRef

Asaka M, Kato M, Kudo M, et al. The role of Helicobacter pylori in peptic ulcer disease. Gastroenterol Jpn 1993; 28 (5 Suppl.): 163–7PubMedCrossRef

Coghlan J, Gilligan D, Humphries H, et al. Campylobacter pylori and recurrence of duodenal ulcers a 12 months followup study. Lancet 1987; II: 1109–11CrossRef

Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431–5PubMed

McCarthy CJ, Collins R, et al. Short report: treatment of Helicobacter pylori associated duodenal ulcer with omeprazole plus antibiotics. Aliment Pharmacol Ther 1993; 7: 463–6PubMedCrossRef

10.

Louw JA, Zak J, Lucke W, et al. Triple therapy with sucralfate is as effective as triple therapy containing bismuth in eradicating Helicobacter pylori and reducing duodenal ulcer relapse rates. Scand J GastroenteroI1992; 27 (191 Suppl.): 28–31

11.

Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308–12PubMedCrossRef

12.

Unge P, Ekstrom P. Effects of combination therapy with omeprazole and antibiotics on Helicobacter pylori and duodenal ulcer disease. Scand J GastroenteroI1993; 28 (196 Suppl.): 17–8

13.

Bayerdorffer E, Mannes GA, et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycilllin. Scand J Gastroenterol 1993; 28 (196 Suppl.): 19–25CrossRef

14.

Miyazaki M, Kato M, Takata T, et al. Intrafamilial transmission of Helicobacter pylori: the association between a parent and offspring with respect to the presence of anti-CagA antibody. I Infect Chemother 2002; 8: 70–5

15.

Milman N, Rosenstock S, Andersen L, et al. Serum ferritin, hemoglobin, and Helicobacterpylori infection: a seroepidemiologic survey comprising 2794 Danish adults. Gastroenterology 2001; 115: 268–74CrossRef

16.

Buckley MJM, O’shea J, Grace A, et al. A comminity-based study of the epidemiology of Helicobacterpylori infection and associated asymptomatic gastroduodenal pathology. Eur J Gastroenterol Hepatol1998; 10: 375–9PubMedCrossRef

17.

Stone MA, Barnett DB, Mayberry JF. Lack of correlation between self-reported symptoms of dyspepsia and infection with Helicobacter pylori, in a general population sample. Eur J Gastroenterol Hepatol 1998; 10: 301–4PubMedCrossRef

18.

Lin SK, Lambert HR, Nicholson L, et al. Prevalence of Helicobacter pylori in a representative Anglo-Celtic population of urban Melbourne. J Gastroenterol Hepatol 1998; 13: 505–10PubMedCrossRef

19.

Stone MA, Patel H, Panja KK, et al. Results of Helicobacter pylori screening and eradication in a multi-ethnic community in central England. Eur J Gastroenterol Hepatol 1998; 10: 957–62PubMedCrossRef

20.

Luzza F, lmeneo M, Maletta M, et al. Suggestion against an oral-oral route of transmission for Helicobacter pylori infection: a seroepidemiological study in a rural area. Dig Dis Sci 1998; 37: 148–50

21.

Us D, Hascelik G. Seroprevalence of Helicobacterpylori infection in an asymptomatic Turkish population. J Infect 1998; 37: 148–50PubMedCrossRef

22.

Ami AE, Malu AO, Queiroz DMM, et al. Determination oflg G antibodies against Helicobacter pylori in adult dyspeptic patients and blood donors from Jos, Nigeria. Med Sci Res 1998; 26: 689–90

23.

Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922–8PubMedCrossRef

24.

Fendrick AM, Chernew ME, Hirth RA, et al. Alternative management strategies for patients with suspected peptic ulcer disease. Ann Intern Med 1995; 123 (4): 260–2688PubMed

25.

Feldman RA, Deeks JJ, Evans SJW. The Helicobacter pylori Serology Study Group. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Eur J Clin Microbiol Infect Dis 1995; 14: 428–33PubMedCrossRef

26.

Juncal AR, Garea MT, Cid A, et al. Assessment of 4 commercial immunoenzymatic assays for the serologic diagnosis of Helicobacter pylori infection. Enferm Infec Microbiol Clin 1998; 16: 185–9

27.

Willson JD, Bramwald E, Isselbacher KJ, et al. editors. Harrison’s Principles of internal Medicine. 12th ed. New York: McGraw Hill, 1991

28.

Feldman RA, Eccersley AJP, Hardie JM. Epidemiology of Helicobacter pylori: acquisition, transmission, population prevalence and disease-to-infection ratio. Br Med Bull 1998; 54: 39–53PubMedCrossRef

29.

Malaty HM, Kim JG, Kim SD, et al. Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996; 143: 257–62PubMedCrossRef

30.

Veldhuyzen van Zanten SJ. Do socio-economic status; marital status and occupation influence the prevalence of Helicobacter pylori infection? Ailment Phannacol Ther 1995; 9 (2 Suppl.): 41–4

31.

Shibata K, Moriyama M, Fukushima T, et al. Green tea consumption and chronic atrophic gastritis: a cross-sectional study in a green tea production village. J Epidemiol 2000; 10: 310–6PubMedCrossRef

32.

Shibata K, Moriyama M, Fukushima T, et al. Relation of Helicobacterpylori infection and lifestyle to the risk of chronic atrophic gastritis: a cross-sectional study in Japan. J Epidemiol 2002; 12: 105–11PubMedCrossRef

33.

Gray I. Tobacco smoking and gastric cancer. Ann Intern Med 1929; 3: 267–77

34.

Korman MG, Show RG, Hansky J. Influences of smoking on healing rate of duodenal ulcer in response to cimetidine or high dose antacid. Gastroenterology 1984; 80: 1451–63

35.

Korman MG, Hansky J, Eaves ER, et al. Influences of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871–3PubMed

36.

Am SK, Koo J. Accurate prediction of duodenal-ulcer healing rate by discriminant analysis. Gastroenterology 1983; 85: 403–11

37.

Kato I, Nomira AM, Stemmermann GN, et al. A prospective study of gastric and duodenal ulcer and its relation to smoking and diet. Am J Epidemol 1992; 135: 521–30

38.

Hirayama T. Life-style and mortality: a large-scale censusbased cohort study in Japan. Basel: Karger, 1990

39.

Takaku F, Ogata E. Practical of internal medicine [in Japanese]. Tokyo: Igakushoin, 1997

40.

Hirota M. Cost evaluation of duodenal ulcer treatment involving eradication of Helicobacter pylori [in Japanese]. Kyoufuidaishi 1996; 105: 121–40

41.

Rothman KJ, Greenland S. Modern epidemiology. Philadelphia (PA): Lippincott-Raven, 1998

42.

International Agency for Research on Cancer. Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177–240

43.

Parsonnet J, Freedman GD, Vandersteen DP, et al. Helicobacter pylori infection and risk of gastric carcinoma. N Engl J Med 1991; 325: 1127–31PubMedCrossRef

44.

Nomura A, Stemrrerman GN, Chyou PH, et al. Helicobacter pylori infection and gastric cancer among Japanese Americans in Hawaii. N Engl J Med 1991; 325: 1132–6PubMedCrossRef

45.

Asaka M, Kimura T, Kato M, et al. Possible role of Helicobacter pylori infection in early gastric cancer development. Cancer 1994; 73: 2691–4PubMedCrossRef

46.

Kikuchi S, Wada O, Nakajima T, et al. Serumanti-Helicobacter pylori antibody and gastric carcinoma among young adults. Cancer 1995; 75: 2789–93PubMedCrossRef

47.

Uermra N, Mukai T, Okamoto S, et al. Effects of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 639–42

48.

Uermra N, Okamoto S, Yamamoto S, et al. Helicobacterpylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–9CrossRef

49.

Xia H, Talley NJ, Keane CT, et al. Recurrence of Helicobacter pylori infection after successful eradication: nature and possible causes. Dig Dis Sci 1997; 42: 1821–34PubMedCrossRef

Title: Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?
Authors: Akira Babazono
Motonobu Miyazaki
Hiroshi Une
Eiji Yamamoto
Toshihide Tsuda
Yoshio Mino
Alan L. Hillman
Publication date: 01-10-2004
Publisher: Springer International Publishing
Published in: PharmacoEconomics / Issue 15/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI: https://doi.org/10.2165/00019053-200422150-00002

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Does Seropositivity for Helicobacter pylori Antibodies Increase Outpatient Costs for Gastric and Duodenal Ulcer or Inflammation?

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 15/2004

Economic Impact of Migraine and Other Episodic Headaches in France

Cost Effectiveness of ACE Inhibitor Treatment for Patients with Type 1 Diabetes Mellitus

Comparisons of Hypertension-Related Costs from Multinational Clinical Studies

Cost Effectiveness of Ramipril in Patients at High Risk for Cardiovascular Events